EUVIMEDEUVIMED entdecken
Crossref

Zbtb32 promotes CD8+ T cell differentiation and function in cancer

Birui Pan iD, Qinli Sun iD, Ruifeng Li iD, Juan Feng iD, Jing Hao iD, Bowen Xie iD, Xiaohong Zhao iD, Zixuan Zhao iD, Peng Wei iD, Qiuyan Lan iD, Shiyuan Xie iD, Tian Xie iD und 6 weitere

Journal of Experimental Medicine · 2026

DOI: 10.1084/jem.20250005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Birui Pan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Immunology, Tsinghua University , Beijing, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Cell Differentiation, Repressor Proteins, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Natural Science Foundation of China, National Key Research and Development Program of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the tumor microenvironment (TME), “exhausted” CD8+ T cells are classified into progenitor (Tpex) and terminally exhausted (Ttex) populations. Tpex cells, critically regulated by zinc finger and BTB domain containing 27 (Zbtb27)/Bcl6 transcription factor, could be reinvigorated during immune checkpoint blockade (ICB) therapy, while Ttex cells, characterized by stronger proliferation and cytotoxicity, play an indispensable role in tumor control. However, the mechanisms governing the differentiation into Ttex and their function remain not well understood. In this study, we identified that Zbtb32, highly expressed in CD8+ Ttex subset, is crucial for CD8+ T cells within tumors. Zbtb32, regulated by CD28 signaling, promotes the differentiation of CD8+ T cells into Ttex subset, enhancing their cytotoxicity, proliferation, and anti-tumor capability. Importantly, we found a competitive DNA binding between Zbtb32 and Bcl6, especially in regulation of Id2 expression. Thus, our findings demonstrate the pivotal role of Zbtb32 in CD8+ T cell anti-tumor function, with implications in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesCell DifferentiationRepressor ProteinsNeoplasmsAnimalsT-Cell ExhaustionHumansMiceProto-Oncogene Proteins c-bcl-6Tumor MicroenvironmentCell ProliferationCD28 Antigens

Substanzen

Proto-Oncogene Proteins c-bcl-6Repressor ProteinsCD28 Antigens

Autor:innen und Institutionen

  • Institute for Immunology, Tsinghua University , Beijing, China.
  • Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital , Shanghai, China.
  • Westlake University School of Medicine , Hangzhou, China.

ORCID-Profile: Birui Pan, Qinli Sun, Ruifeng Li, Juan Feng, Jing Hao, Bowen Xie, Xiaohong Zhao, Zixuan Zhao, Peng Wei, Qiuyan Lan, Shiyuan Xie, Tian Xie, Yongzhen Chen, Kun Wei, Xuan Zhong, Hai Qi, Ling Ni, Chen Dong

Förderung

  • Natural Science Foundation of China
  • National Key Research and Development Program of China
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Pan, B., Sun, Q., Li, R., Feng, J., Hao, J., Xie, B., Zhao, X., Zhao, Z., Wei, P., Lan, Q., Xie, S., Xie, T., Chen, Y., Wei, K., Zhong, X., Qi, H., Ni, L., & Dong, C. (2026). Zbtb32 promotes CD8+ T cell differentiation and function in cancer. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20250005

Vancouver

Pan B, Sun Q, Li R, Feng J, Hao J, Xie B, et al. Zbtb32 promotes CD8+ T cell differentiation and function in cancer. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20250005

BibTeX
@article{Pan2026,
  author = {Pan, Birui and Sun, Qinli and Li, Ruifeng and Feng, Juan and Hao, Jing and Xie, Bowen and Zhao, Xiaohong and Zhao, Zixuan and Wei, Peng and Lan, Qiuyan and Xie, Shiyuan and Xie, Tian and Chen, Yongzhen and Wei, Kun and Zhong, Xuan and Qi, Hai and Ni, Ling and Dong, Chen},
  title = {Zbtb32 promotes CD8+ T cell differentiation and function in cancer},
  journal = {Journal of Experimental Medicine},
  year = {2026},
  doi = {10.1084/jem.20250005}
}
Kostenlos starten →